Clinical Trial Update: Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating verteporfin added to ranibizumab for symptomatic polypoidal choroidal vasculopathy; efficacy and safety results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• Lucentis (ranibizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: Novartis | Conditions: Polypoidal Choroidal Vasculopathy | Phase 4 | Status: COMPLETED | Results posted: 2011-01-25